Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation

Optimal anticoagulation using heparin with close attention to maintain therapeutic dosing during the procedure is important.

Randomized comparison of continuous and intermittent heparin infusion during catheter ablation of Atrial Fibrillation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coagulation; Intravascular Cardiovascular Diseases Embolism and Thrombosis Thrombosis Vascular Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Seoul st. mary's hospital

Seoul, South Korea

About this study

Intravenous heparin was used during the procedure to prevent catheter-induced thrombosis.

heparin is administered during the procedure to achieve recommended activation clotting times (ACT) values, typically >300 seconds to prevent thromboemboli during the procedure.

Most of the practitioners was that ACT level should be checked at 30- to 60-minute intervals and then have injected intermittently.

intermittent heparin infusion, concentration is great changed because the heparin has 30minutes half-period.

researchers postulate that a constant therapeutic concentrations would be beneficial to continuous infusion than intermittent infusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Atrial Fibrillation, Radiofrequency catheter ablation scheduled

Exclusion criteria

Clinical trial denied

Treatment and study plan

Continuous heparin infusion

Drug

continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.

Intermittent heparin infusion

Drug

Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.

Primary outcomes

therapeutic ACT retention rate during procedure

Time frame: 2 years

Sponsors and collaborators

Lead sponsor

Yong Seog Oh

Other

Registry information

Acronym: COHERE

Important dates

Study start: 2012
Primary completion: 2015
Study completion: 2015
First posted: Sep 5, 2013
Registry last updated: Apr 14, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed